Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients

Vandana Singh
·1 min read

  • Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NASDAQ: RCUS) announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

  • The study evaluates the combinations of domvanalimab + zimberelimab (doublet) and domvanalimab + zimberelimab + etrumadenant (triplet) versus zimberelimab monotherapy.

  • Related: Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures.

  • The doublet and triplet combinations demonstrated clinically meaningful improvements in median progression-free survival (PFS) and six-month landmark PFS rates compared to zimberelimab monotherapy, with a 45% reduction in risk of disease progression or death for the doublet and 35% for the triplet.

  • Each of the domvanalimab-containing study arms also demonstrated clinically meaningful improvements in objective response rate (ORR) compared to zimberelimab monotherapy. Confirmed ORR was 27%, 41%, and 40% for the zimberelimab monotherapy arm and the domvanalimab-doublet and -triplet arms, respectively.

  • While the triplet arm did not show an improvement over the doublet arm, it reinforces the results observed in the doublet arm.

  • The study will continue to monitor PFS and overall survival for the triplet arm as these data mature.

  • No unexpected safety signals were observed across the three study arms. The domvanalimab-containing study arms were generally well tolerated and showed an overall safety profile.

  • Price Action: GILD shares are down 5.25% at $81.89, and RCUS shares are down 31% at $21.25 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.